Investor  Relations

Regen BioPharma Inc. is a publicly traded biotechnology company (OTC PINK: RGBP) and (OTC PINK: RGBPP). The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

For regulatory filings by the company, click here
For regulatory filings by the company, click here

Investor Resources

Regulatory Filings

8-K 12-8-2022 Filed 2-18-2022